Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829504 · ClinicalTrials.gov registry record · Phase 1
Ropinirole 0.25 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00829504: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00829504 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829504, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under fasting conditions in healthy, non-smoking, adult subjects.
Interventions
- DRUG Ropinirole HCl 0.25 mg Tablets
- DRUG Requip® 0.25 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829504
The ClinicalTrials.gov registry entry for NCT00829504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ropinirole HCl 0.25 mg Tablets is the first listed.
NCT00829504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829504 about?
NCT00829504 is a clinical study titled "Ropinirole 0.25 mg Tablets Under Fasting Conditions". The objective of this study was to compare the relative bioavailability of the test formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under fasting conditions in healthy, non-smokin...
What is the current status of trial NCT00829504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00829504?
The interventions under investigation include: Ropinirole HCl 0.25 mg Tablets (DRUG), Requip® 0.25 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00829504?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.